New Protocols (0*)
Updated Protocols (1*)
Breast Cancer
- Pembrolizumab 200 / Doxorubicin 60 / Cyclophosphamide 600, Breast Ca, neoadjuvant, cycle 5-8 PID 1466 V1.1 (2024-04-23)V1.1: Correction of antiemesis with addition of Dexamethasone, addition of controls, revision of recommendations, addition of therapy sequence V1.0: Cato test done. V0.1: Duration and sequence according to summary of product characteristics. Duration of Doxorubicin according to the volume of the carrier solution, replacement of Granisetron by Palonosetron and omission of a corticosteroid according to Della Corte.
Protocols in Revision
Hemophagocytic Lymphohistiocytosis
- PAED Methotrexate 12, Hemophagocytic Lymphohistiocytosis PID 672 V1.2
Bladder Cancer
- Sacituzumab Govitecan 10, Bladder Cancer PID 2000 V1.1
Hodgkin Lymphoma
- Nivolumab 240 / Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma PID 1970 V1.1
- Nivolumab 240 / Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma, Part B PID 1375 V1.2
Colon Cancer
- Fluorouracil 2600 / Sodium Folinate 500, Colorectal Carcinoma PID 51 V1.1
- Irinotecan 80 / Sodium Folinate 500 / Fluorouracil 2000, Colorectal Carcinoma PID 1157 V1.1
- Oxaliplatin 100 / Sodium Folinate 400 / Fluorouracil 2400, Colorectal Carcinoma PID 1175 V1.1
- Trastuzumab Deruxtecan 6.4, Colorectal Carcinoma PID 2357 V1.1
Head and Neck Tumors (Squamous Cell)
- Pembrolizumab 200 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, first-line PID 1446 V1.1
Lung Carcinoma, Small Cell
- Durvalumab 1500 / Carboplatin 5 / Etoposide 100, Small Cell Lung Carcinoma PID 1593 V1.2
- Pembrolizumab 200 / Carboplatin 5 / Etoposide 100, Lung Carcinoma, Small Cell PID 630 V1.1
Lung Carcinoma, Non-Small Cell
- Pembrolizumab 200 / Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer PID 35 V1.2
- Pembrolizumab 200 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer PID 842 V1.4
Breast Cancer
- Pembrolizumab 200 / Carboplatin 2 / Gemcitabine 1000, Breast Cancer PID 1933 V2.1
- Sacituzumab Govitecan 10, Breast Cancer PID 1780 V1.2
Multiple Myeloma
- Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Isatuximab 10, multiple myeloma, induction, IB, cycle 1 PID 41 V1.2
- Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Isatuximab 10, multiple myeloma, induction, IB, cycle 2-3 PID 42 V1.2